JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ramsay, R. R.
Right arrow Articles by Singer, T. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ramsay, R. R.
Right arrow Articles by Singer, T. P.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J. Biol. Chem., Vol. 261, Issue 17, 7585-7587, 06, 1986

Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria

RR Ramsay and TP Singer

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), an impurity in certain batches of illicit heroin substitutes, is known to cause parkinsonian symptoms and degeneration of the nigrostriatal cells in drug abusers and primates. Neurotoxicity depends on oxidation of MPTP by monoamine oxidase in brain cells to the dihydropyridinium form, which is further oxidized to N-methyl-4-phenylpyridinium (MPP+), the 4- electron oxidation product. The latter is widely believed to be the compound responsible for neuronal destruction and the NADH dehydrogenase of the inner membrane has been postulated to be its target. This enzyme is inhibited, however, only at very high concentrations of MPP+, while the steady-state concentration of MPP+ in the nigrostriatal cells of MPTP-treated animals is several orders of magnitude lower. This paradox has now been resolved by the discovery of an energized uptake system for MPP+ in mitochondria which rapidly concentrates MPP+ to very high concentrations in the mitochondria at micromolar external concentrations. The process is dependent on the electrical gradient of the membrane, has a Km of about 5 mM, and is completely blocked by respiratory inhibitors and uncouplers.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Neurosci.Home page
R. M. Solano, M. J. Casarejos, J. Menendez-Cuervo, J. A. Rodriguez-Navarro, J. Garcia de Yebenes, and M. A. Mena
Glial Dysfunction in Parkin Null Mice: Effects of Aging
J. Neurosci., January 16, 2008; 28(3): 598 - 611.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
B. Sredni, R. Geffen-Aricha, W. Duan, M. Albeck, F. Shalit, H. M. Lander, N. Kinor, O. Sagi, A. Albeck, S. Yosef, et al.
Multifunctional tellurium molecule protects and restores dopaminergic neurons in Parkinson's disease models
FASEB J, June 1, 2007; 21(8): 1870 - 1883.
[Abstract] [Full Text] [PDF]


Home page
QJMHome page
A.C. Williams, L.S. Cartwright, and D.B. Ramsden
Parkinson's disease: the first common neurological disease due to auto-intoxication?
QJM, March 1, 2005; 98(3): 215 - 226.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
K. Nakamura, V. P. Bindokas, J. D. Marks, D. A. Wright, D. M. Frim, R. J. Miller, and U. J. Kang
The Selective Toxicity of 1-Methyl-4-phenylpyridinium to Dopaminergic Neurons: The Role of Mitochondrial Complex I and Reactive Oxygen Species Revisited
Mol. Pharmacol., August 1, 2000; 58(2): 271 - 278.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
R. G. W. Staal, K. A. Hogan, C.-L. Liang, D. C. German, and P. K. Sonsalla
In Vitro Studies of Striatal Vesicles Containing the Vesicular Monoamine Transporter (VMAT2): Rat versus Mouse Differences in Sequestration of 1-Methyl-4-phenylpyridinium
J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 329 - 335.
[Abstract] [Full Text]


Home page
Mol. Pharmacol.Home page
Y. Kitamura, T. Kosaka, J.-I. Kakimura, Y. Matsuoka, Y. Kohno, Y. Nomura, and T. Taniguchi
Protective Effects of the Antiparkinsonian Drugs Talipexole and Pramipexole against 1-Methyl-4-phenylpyridinium-Induced Apoptotic Death in Human Neuroblastoma SH-SY5Y Cells
Mol. Pharmacol., December 1, 1998; 54(6): 1046 - 1054.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
R. H. Moseley, L. J. Zugger, and R. W. Van Dyke
The Neurotoxin 1-Methyl-4-phenylpyridinium Is a Substrate for the Canalicular Organic Cation/H+ Exchanger
J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 34 - 40.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
P. Chan, D. A. Di Monte, J. W. Langston, and A. M. Janson
(+)MK-801 Does Not Prevent MPTP-Induced Loss of Nigral Neurons in Mice
J. Pharmacol. Exp. Ther., January 1, 1997; 280(1): 439 - 446.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 1986 by the American Society for Biochemistry and Molecular Biology.